Pluri (US:PLUR)2020-10-19 19:06Company Overview - Pluristem Therapeutics is a cell therapy company focused on regenerative medicine, utilizing placenta-derived cell product candidates[5] - The company had approximately $59 million in cash as of June 30, 2020 and employs around 160 full-time employees[5] - Pluristem's technology allows manufacturing of treatments for over 20,000 patients per placenta[11,12,19] Clinical Programs - PLX-PAD aims to treat Critical Limb Ischemia (CLI) by reducing inflammation and stimulating blood vessel growth[28] - A Phase I/II study of PLX-PAD for muscle injury following total hip replacement (N=20) showed a 300% improvement in muscle volume (p=0.004), a 500% improvement in strength compared to the non-operated side (p=0.0067), and a 4000% improvement in strength compared to placebo (p=0.012)[36] - In a compassionate use program, 87.5% survival rate was observed in ventilator-dependent COVID-19 patients treated with PLX-PAD[53] Financials and Partnerships - The EIB (European Investment Bank) signed a €50 million non-dilutive financing agreement with Pluristem to support R&D in the EU[66] - EIB will support up to 50% of the cost of the project[66] - EIB would be entitled to receive royalties from future revenues for a period of seven years starting 2024, at a rate of 0.2% to 2.3%, pro-rated to the amounts that the Company received[67]